

Quantification of Biological Aging

Daniel W. Belsky, PhD

Assistant Professor

Department of Epidemiology & Robert N Butler Columbia Aging Center

Columbia University Mailman School of Public Health

daniel.belsky@columbia.edu

@danbelsky


 COLUMBIA UNIVERSITY | MAILMAN SCHOOL
of PUBLIC HEALTH

 COLUMBIA | AGING CENTER
THE ROBERT N. BUTLER COLUMBIA AGING CENTER


Disclosures

DWB is listed as an inventor on a Duke University and University of Otago invention (DunedinPACE) that has been licensed to a commercial entity

Aging is a biological process
 a gradual and progressive decline in system integrity




Kirkwood 2005



Kennedy et al.
 2014 Cell

Lopez-Otin et al.
 2013 Cell






A geroscience model of aging-related burden of disease

Molecular
Changes

Decline in
System
Integrity


Functional
Decline

Disease
Disability
Mortality




Geroprotective intervention

Molecular
Changes




Decline in
System
Integrity



Functional
Decline




Disease
Disability
Mortality



Why do we need measures of biological aging?

1. Testing effects of geroprotective interventions

Decades of follow-up are needed to test effects on healthspan. Changes in biological aging could be measured in years.




2. Clinical risk assessment and prognosis

Chronological age is a crude measure. We can improve precision for timing screening, monitoring health, and forecasting potential outcomes of intervention



3. Population surveillance and program/policy evaluation

Monitoring changes in population health from data on lifespan, disease burden, or healthcare utilization gets us answer too late. Sensitive measures enable faster action and aid calculation of benefit/cost ratios



What is a biological age?

The age at which a person's biology would be "normal" in a reference population




Figure – Benayoun et al. 2015 Nat Rev Mol Biol

What is a biological age?

The **age** at which a person's **biology** would be “**normal**” in a **reference population**




Figure – Benayoun et al. 2015 Nat Rev Mol Biol

What is a biological age?

The age at which a person's biology would be “normal” in a **reference population**

Healthspans and lifespans vary across places, populations, historical periods

Metrics of biological aging are scaled relative to the sample in which they are developed

The sample used for development should reflect the distribution of causes and features of aging in the population in which the measurement will be used




Figure – Benayoun et al. 2015 Nat Rev Mol Biol

What is a biological age?

The age at which a person's **biology** would be “normal” in a reference population

Biology can be observed at multiple levels of analysis/organization


There are reciprocal interactions across levels

Cellular Level

- Epigenetics
- Transcriptomics
- Proteomics
- Metabolomics
- Etc.

Organs/ Organ-systems


- Organ function testing
- Body composition
- Blood chemistries



What is a biological age?

The **age** at which a person's biology would be "normal" in a reference population

- **Time since birth**
BA = differences between older and younger people
- **Time until death**
BA = differences in mortality risk
- **Coordination across biological systems**
BA = system integrity



Klemera-Doubal method BA
First-gen DNAm clocks
(Horvath, Hannum, many others)

PhenoAge (Levine),
GrimAge (Lu)

PCA-based
methods,
homeostatic
dysregulation
(Cohen)

Limitations of Biological Age

- **Survival Bias**
Older people necessarily represent slower agers (because the faster agers have died)
- **Cohort Effects**
People born at different times in history grow up under different exposure regimes (pathogens, toxicants, healthcare technology, health behavior norms)
- **Uncertain Timing**
Uncertain if older/younger biological age reflect ongoing processes of aging or were established early in life


An alternative: Pace of Aging



Pace of Aging is the rate of decline in system integrity

- Aging = *changes* within individuals' bodies/cells


In our work, we measure Pace of Aging from declines in integrity across multiple organ systems




[Belsky et al. 2015 PNAS](#)
[Elliott et al. 2021 Nat Aging](#)

DunedinPACE: A DNAm blood test for the Pace of Aging

Dunedin Birth Cohort Follow-up



20-year Pace of Aging




- Young adulthood-midlife follow-up excludes dropout from morbidity / mortality
- Single birth cohort excludes cohort effects
- Repeated measures to quantify change over 2 decades of follow-up

Technical improvements to the DNA methylation algorithm


- Use of higher-reliability probes on Illumina arrays to improve test-retest reliability
- Internal normalization to enable single-sample analysis

DunedinPACE has excellent test-retest reliability


Essential for testing within-individual change from pre-treatment baseline to follow-up




Data from [GSE55763](#)



DunedinPACE shows similar prediction of mortality morbidity, and disability to GrimAge






Mortality in the Normative Aging Study & Framingham Heart Study



Incident Cardiovascular Disease, Stroke/TIA, and Dementia in the Framingham Heart Study

*GrimAge was developed to predict mortality within this dataset

Testing geroprotection in the CALERIE RCT



DNAm measured from blood at baseline, 12mo, 24mo (n=197)



CALERIE intervention slows aging as measured by blood-chemistry biological age measures






Fig. 3 Change in Klemera-Doubal method (KDM) Biological Age, PhenoAge, and homeostatic dysregulation (HD) from Baseline to 12- and 24-month follow-ups in the ad libitum (dark blue dots) and caloric-restriction (light blue triangles) groups of the CALERIE trial. The figure plots predicted values and 95% confidence intervals estimated from mixed-effects growth models for participants in the ad libitum control group (dark blue circles, solid line) and caloric restriction intervention group (light blue triangles, dashed line). Values of KDM Biological Age and PhenoAge are denominated in years. Values of HD are denominated in log units

Kwon et al. 2021 [Geroscience](#)
See also Belsky et al. 2017 *J Geron A*

1st Gen. Clocks

Developed to predict chronological age in mixed-age samples



Expected change is 1y per 12mo



2nd Gen. Clocks

Developed to predict mortality risk in mixed-age samples



Expected change is 1y per 12mo



Pace of Aging

Developed to predict decline in system integrity in a birth cohort followed over time

Expected change is ~ 0



Models adjusted for baseline chronological age, sex, race, study site, and baseline BMI stratum





CALERIE RCT Treatment Effects

Only DunedinPACE showed consistent, statistically significant effects of treatment

Why?

- Superior test-retest reliability (less error in measurement)




CALERIE RCT Treatment Effects

Only DunedinPACE showed consistent, statistically significant effects of treatment


Why?

- Superior reliability
- Pace of Aging method may be more sensitive to treatment effects





Conclusions and next steps



- Methods to quantify processes of biological aging represent new tools for aging science
- DunedinPACE is a new addition to this toolkit that is conceptually distinct from “clock” methods and may offer value added, especially for intervention studies
- Measures of biological aging open new frontiers to study interventions in young and midlife populations, esp. on health behavior, environmental toxicants, and social determinants
- Measures of biological aging may also provide new clinical tools for risk assessment and prognosis



Code to compute DunedinPACE from Illumina 450k and EPIC Array data is available on GitHub



Code to implement DunedinPoAm in Illumina 450k or EPIC array data at <https://github.com/danbelsky/DunedinPACE>



National Institute
on Aging

CIFAR

Thank you!



RUSSELL SAGE
FOUNDATION




JACOBS
FOUNDATION

Our Promise to Youth

DunedinPACE indicates faster Pace of Aging in individuals with older chronological and biological age



N=1,175



We expect the rate of aging to accelerate at older chronological ages parallel to acceleration in mortality risk



This hypothesis is not testable with standard DNAm clocks because their measure of “age acceleration” is uncorrelated with chronological age by design

e.g. Finch & Crimmins 2016 PNAS


DunedinPACE indicates faster Pace of Aging in individuals with older chronological and biological age




N=1,175



DunedinPACE shows similar prediction of mortality morbidity, and disability to GrimAge



Incident and Prevalent Chronic Disease in the Normative Aging Study





Incident Disability in the Framingham Heart Study

DunedinPACE is faster in adolescents with histories of childhood adversity

E-RiSK
Study

N=1,116
Age 18 blood samples








<https://calerie.duke.edu/>




Calorie restriction (CR), macronutrient restriction with maintenance of micronutrient sufficiency, is the best-established geroprotective intervention in animals


CALERIE is the first-ever RCT of long-term CR in healthy, non-obese humans




Weindruch & Walford 1982 Science
Colman et al. 2009 Science
Mattison et al. 2014 Nature
Colman et al. 2014 Nat Comm



CALERIE randomized n=220 non-obese adults to 25% CR for 24 months
n=145 CR Treatment
n=75 AL Control



Adherence was imperfect
Average CR was 12% in the treatment group and ~2% in the control group




CALERIE RCT Treatment Effects

The GrimAge clock and both Pace of Aging measures indicate evidence of slowed aging in the CR treatment group

Only DunedinPACE showed consistent, statistically significant treatment effects




Why DunedinPACE?

- Superior reliability
- Pace of Aging method may be more sensitive to treatment effects



Intent-to-Treat (ITT) effect-sizes scaled in baseline standard-deviation units, estimated from repeated measures ANCOVA

CALERIE Treatment Effects
are not explained by special
sensitivity of DunedinPACE
to weight loss




Code to compute blood-chemistry biological age measures from custom biomarker sets is available on GitHub








Code to implement KDM BA, PhenoAge, and Homeostatic Dysregulation methods
<https://github.com/dayoonkwon/BioAge>

Progress in development of biological age indices (in humans)

- Improved measurement of sub-clinical health states (better prediction of morbidity and mortality)
- Increasing sophistication of methods for data mining (deep learning, neural networks)
- Increasing diversity of molecular data incorporated into studies of aging (proteomics, metabolomics)
- Emerging multi-omics datasets and analysis methods



Galkin et al. 2021
Aging & Disease

Telomere	Epigenetics	Transcriptomics	Proteomics	Metabolomics
				
-Leukocyte DNA -qPCR -Telomere length -N=2936	-Whole blood DNA -MBD-seq -28M CpGs -N=1130	-Whole blood RNA -Micro arrays -18K genes -N=1990	-Whole blood serum -Immunoassay -171 proteins -N=1837	-Whole blood plasma -Nightingale platform -231 Metabolites -N=2910

Jansen et al. 2021 eLife

Frontiers

- **Biology is still unknown**
Algorithms remain black boxes. But in-vitro studies are advancing knowledge.
- **Reporting is uneven**
Many studies still argue proof of concept from prediction of chronological age without reference to other validation metrics
- **External validity is unproven**
Only recently have studies moved beyond the well-off, well-educated, White, and “bio-curious” volunteers
- **Modifiability is uncertain**
Intervention studies testing change are just beginning
- **Significance of change is unclear**
Longitudinal data are needed to establish whether changes in measures of aging correspond to changes in healthspan

Horvath & Raj 2018 Nat Rev Genet
Bell et al. 2019 Genom Biol
Sturm et al. 2019 Epigenetics
Liu et al. 2020 Aging Cell

Belsky et al. 2017 Aging Cell
Belsky et al. 2017 J Geron A
Belsky et al. 2018 AJE
Hastings et al. 2019 PNE
Parker et al. 2019 J Geron A
Belsky & Kothari 2021 eLife
Graf et al. 2021 AJE

Limitations of Biological Age as a surrogate for geroprotector trials

- **Mortality Selection** - Older and younger individuals represent different populations

Biological Age measures may underestimate true aging because older participants necessarily represent slower agers





Figure 2. The mean number of degraded loci per individual when loci cause aging (grey), or are neutral (dashed black) out of 301 total loci. We use the largest effect size shown in Figure 3, where the degradation of one causative locus results in a 2.3% increase in mortality rates in an otherwise non-degraded individual, and all loci have an expected age of degradation of 75 years.

Limitations of Biological Age as a surrogate for geroprotector trials

- **Cohort Effects** - Between-individual comparisons do not distinguish aging from cohort exposure history
 - Biological Age measures may overestimate true aging because older participants carry excess burden of early-life exposure to environmental toxicants, pathogens, poor nutrition, smoking, etc.




[Moffitt et al. 2016 J Geron A](#)

Limitations of Biological Age as a surrogate for geroprotector trials

- **Uncertain Timing** - Unclear when “age acceleration” occurs

Biological Age measures summarize total aging over the lifespan and do not distinguish differences established early in development from ongoing processes of aging

May result in lower sensitivity to effects of intervention



[Gladyshev 2020 Trend Mol Med](#)

Measuring Pace of Aging: Theory

Aging is characterized by a gradual and progressive decline in system integrity



The rate of aging can be inferred from the rate of decline in integrity across multiple organ systems

This decline should be observable already by young adulthood





Pace of Aging is a longitudinal measure of the *rate* of decline in system integrity

- Young Adulthood- Midlife follow-up excludes dropout from morbidity / mortality
- Single birth cohort excludes cohort effects
- Repeated measures to quantify change



Belsky et al. 2015 PNAS

A DNAm surrogate for Pace of Aging: DunedinPoAm



Molecular Changes

Decline in System Integrity

Functional Decline

Disease Disability Mortality



RESEARCH ARTICLE



Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm

Daniel W Belsky^{1,2*}, Avshalom Caspi^{3,4,5,6}, Louise Arseneault³, Andrea Baccarelli⁷, David L Corcoran⁶, Xu Gao⁷, Eiliss Hannon⁸, Hona Lee Harrington⁴, Line JH Rasmussen^{4,9}, Renate Houts⁴, Kim Huffman^{10,11}, William E Kraus^{10,11}, Dayoon Kwon², Jonathan Mill⁹, Carl F Pieper^{11,12}, Joseph A Prinz⁶, Richie Poulton¹³, Joel Schwartz¹⁴, Karen Sugden⁴, Pantel Vokonas¹⁵, Benjamin S Williams⁴, Terrie E Moffitt^{3,4,5,6}

Testing Black-White disparities in biological aging in older adults in the United States: analysis of DNA-methylation and blood-chemistry methods

Gloria H Graf, Christopher L Crowe, Meeraj Kothari, Dayoon Kwon, Jennifer J Manly, Indira C Turney, Linda Valeri, Daniel W Belsky ✉

American Journal of Epidemiology, kwab281,


<https://doi.org/10.1093/aje/kwab281>

Published: 01 December 2021 **Article history** ▾



HRS | HEALTH AND RETIREMENT STUDY



N=3,491
Mean Age=70
Blood DNAm



Socioeconomic Disadvantage and the Pace of Biological Aging in Children

Laurel Raffington, PhD,^{a,b} Daniel W. Belsky, PhD,^{c,d} Meeraj Kothari, MPH,^d Margherita Malanchini, PhD,^{a,b,e}
Elliot M. Tucker-Drob, PhD,^{a,b,*} K. Paige Harden, PhD^{a,b,*}

PEDIATRICS®




N=600
Mean Age=13
Saliva DNAm



Social mobility and biological aging among older adults in the United States

GH Graf, Y Zhang, BW Domingue, KM Harris, M Kothari, D Kwon, P Muennig, DW Belsky

doi: <https://doi.org/10.1101/2021.10.19.465042>



HRS | HEALTH AND
RETIREMENT
STUDY